3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
24
Neoplasm Metastasis
11
Stomach Neoplasms
6
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Salivary Gland Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Interventions
Nivolumab
37
pembrolizumab
30
cabozantinib
27
Specimen Handling
25
Magnetic Resonance Spectroscopy
22
Ipilimumab
20
lenvatinib
16
Axitinib
15
belzutifan
13
CTLA-4 Antigen
10
Sunitinib
9
Biopsy
9
Radiosurgery
8
atezolizumab
7
Immunoglobulin G
5
toripalimab
4
fludarabine
4
avelumab
4
aldesleukin
4
Everolimus
4
Disulfides
4
Cyclophosphamide
4
zimberelimab
3
tivozanib
3
spartalizumab
3
pazopanib
3
palbociclib
3
durvalumab
3
cemiplimab
3
X-Rays
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
trastuzumab deruxtecan
×
90 days
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled